An Open-Label Randomized Phase 3 Study of Capecitabine 6 months versus Capecitabine 12 months as Adjuvant Chemotherapy for Stage 3(Dukes'C) Colon Cancer Patients

Trial Profile

An Open-Label Randomized Phase 3 Study of Capecitabine 6 months versus Capecitabine 12 months as Adjuvant Chemotherapy for Stage 3(Dukes'C) Colon Cancer Patients

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Colon cancer; Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2016 Status changed from active, no longer recruiting to completed, according to to final results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Primary endpoint (Disease-free survival) has not been met, according to final results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Final results of this study, presented at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top